Gender differences in clinical trials of XXXX : An analysis of aggregated data.

@entity1 @entity1277 @entity5550 @entity2749
OBJECTIVE: The aim of the study was to examine gender differences in baseline and outcome variables in clinical trials for @entity5550 ( @entity5550 ). METHOD: Data from 11 randomized controlled psychosocial treatment studies were aggregated (N = 1,325: 208 male, 1,117 female). Baseline and outcome symptoms were assessed via the interview and questionnaire versions of the @entity1277 Examination (EDE). Multilevel analyses were conducted investigating gender differences at baseline and posttreatment, defined as EDE scores, @entity2749 ( @entity2749 ) reduction, and @entity2749 remission at termination. RESULTS: Few males from low socioeconomic status or minority groups participated in the outcome studies. Males reported significantly lower EDE global, shape, weight, and eating concerns at baseline. No main effects of gender were found in treatment outcome scores when controlling for baseline differences; however, baseline EDE global score (which showed gender differences at baseline) and OBEs directly predicted outcome for both males and females. A significant interaction between gender, treatment length, and shape/weight concerns indicated that males with lower shape/weight concerns achieved @entity2749 remission in shorter treatments, whereas @entity1 with high shape/weight concerns and @entity1 with either high or low shape/weight concerns were more likely to achieve @entity2749 remission in treatments of longer duration. CONCLUSIONS: These results suggest @entity5550 treatment studies must improve their recruitment of @entity1 and appeal to @entity1 with lower shape/weight concerns. Additionally, longer term treatments, although more efficacious for @entity1 and @entity1 with more severe shape/weight concerns, may not be necessary for @entity1 with low shape/weight concerns. (PsycINFO Database Record
